The brand new collaboration will dsicover AstraZeneca researchers working side-by-side with experts from the Max Planck Institute of Molecular Physiology, in the Division of Chemical substance Biology, led by Professor Herbert Waldmann. The satellite television unit will concentrate on novel chemistry and chemical substance biology in regions of brand-new modality chemistry such as for example stabilised peptides, conjugation and macrocycles chemistry. Marcus Schindler, Vice President and Mind of CVMD iMed, AstraZeneca, said: I’m happy to collaborate with an internationally recognised educational institution like the Max Planck Institute of Molecular Physiology. Predicated on our exceptional ongoing collaboration with Professor Waldmann’s group and the interdisciplinary Chemical substance Genomics Centre, we have been confident that this latest partnership can lead to exciting scientific findings, addressing chemical challenges in neuro-scientific new modalities primarily.The findings highlight the potential for sleep apnea, a notoriously underdiagnosed condition, to end up being misdiagnosed as despair. Related StoriesNew research finds insufficient proof for use of Omega 3 products in treating main depressive disorderNegative body image significantly increases obesity risk among adolescentsStudy suggests a neural pathway through which early life stress may contribute to depressionStudy results are published in the September problem of the Journal of Clinical Rest Medicine.